Login to Your Account


NewCo News

Labrys Biologics Snags $31M Series A, CEO and Pfizer MAb

By Marie Powers
Staff Writer

Friday, January 4, 2013
Labrys Biologics Inc. burst on the biotech scene with a $31 million Series A, a new president and CEO and the acquisition of a Phase II-ready anti-calcitonin gene-related peptide (CGRP) humanized monoclonal antibody (MAb) from Pfizer Inc. to treat chronic migraine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

For Sales Inquiries,
http://clarivate.com/life-sciences/news/bioworld/#

 
Privacy Policy | Terms of Use | Copyright
 
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Clarivate Analytics